Join
Live feed
·
PRReleasevia Quantisnow
Mainz Biomed N.V. logo

Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

ByQuantisnow·Wall Street's wire, on your screen.
MYNZ· Mainz Biomed N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MYNZ (Mainz Biomed N.V.) and more on Quantisnow.